Active, not recruitingPhase 2NCT04022213

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Studying Desmoplastic small round cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Emily Slotkin, MD
Memorial Sloan Kettering Cancer Center
Intervention
131 I-omburtamab(drug)
Enrollment
31 enrolled
Eligibility
1 years · All sexes
Timeline
20192026

Study locations (1)

Collaborators

Y-mAbs Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04022213 on ClinicalTrials.gov

Other trials for Desmoplastic small round cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Desmoplastic small round cell tumor

← Back to all trials